Media headlines about Aceto (NASDAQ:ACET) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aceto earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.5586460667738 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Top Insights on the Global Acetone Market| Technavio (markets.financialcontent.com)
- Aceto Corp. breached its 50 day moving average in a Bullish Manner : ACET-US : December 11, 2017 (finance.yahoo.com)
- Prosperity of Industrialization to Drive Glucoronolacotane Market During 2017 – 2025 (sbwire.com)
- Aceto Corporation (ACET) Given Average Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Analyzing Lannett (LCI) & Aceto (ACET) (americanbankingnews.com)
Shares of Aceto (NASDAQ ACET) opened at $10.50 on Thursday. Aceto has a 52-week low of $8.29 and a 52-week high of $22.46. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.46 and a current ratio of 2.06. The firm has a market cap of $316.45, a PE ratio of 8.76, a P/E/G ratio of 0.98 and a beta of 1.38.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Monday, December 18th will be paid a dividend of $0.065 per share. This represents a $0.26 annualized dividend and a yield of 2.48%. The ex-dividend date is Friday, December 15th. Aceto’s payout ratio is 123.82%.
Several equities research analysts recently weighed in on ACET shares. Canaccord Genuity set a $15.00 price objective on shares of Aceto and gave the stock a “buy” rating in a research report on Monday, October 30th. Zacks Investment Research cut shares of Aceto from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 9th. Finally, ValuEngine raised shares of Aceto from a “hold” rating to a “buy” rating in a research report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $15.00.
WARNING: This report was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2017/12/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-aceto-acet-share-price.html.
Aceto Corporation (Aceto) is engaged in the marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals inclusive of agricultural intermediates and agricultural protection products.
Receive News & Ratings for Aceto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aceto and related companies with MarketBeat.com's FREE daily email newsletter.